2013
DOI: 10.4161/mabs.22771
|View full text |Cite
|
Sign up to set email alerts
|

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Abstract: Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties, mAbs, 5:1, 22-33,

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
301
2
9

Year Published

2013
2013
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 303 publications
(312 citation statements)
references
References 80 publications
0
301
2
9
Order By: Relevance
“…31,32 The identity of the epitopes can be deciphered through either structural 33 or functional methods. 34 The latter procedures are based on the identification of energetically critical residues contributing to epitope formation.…”
Section: Discussionmentioning
confidence: 99%
“…31,32 The identity of the epitopes can be deciphered through either structural 33 or functional methods. 34 The latter procedures are based on the identification of energetically critical residues contributing to epitope formation.…”
Section: Discussionmentioning
confidence: 99%
“…18 Indeed, the antibody may promote tumor antigen uptake and peptide presentation by dendritic cells, REVIEW REVIEW properties are not simply dependent upon the CD20 epitopes recognized by the antibodies. 25 RTX, like other unconjugated IgG1 antibodies, presents two types of binding: (1) Specific, through binding of Fab region of antibody to the CD20 target antigen ( Fig. 2A) and (2) Nonspecific, through binding of the antibody Fc region to Fcγ receptors (FcγR) on the immune effector cells, to the neonatal Fc receptor (FcRn) on different cell types and to C1q, the first complement component (Fig.…”
Section: Rtx Pdmentioning
confidence: 99%
“…Obinutuzumab conformational structure is different to that of rituximab. First, obinutuzumab binds CD20 in a different overlapping epitope than rituximab, and in a different orientation [Klein et al 2013;Niederfellner et al 2011]. In comparison with rituximab, obinutuzumab is rotated 90° around the Fab middle axis and tilts 70° toward the carboxy terminus of the CD20 epitope.…”
Section: Obinutuzumab a New Class Of Anti-cd20 Mabsmentioning
confidence: 99%